ReviewWorld journal of gastroenterology2026
Molecular mechanisms of tumor-associated macrophages in hepatocellular carcinoma development and therapy.
Review in World journal of gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Metabolic symbiosis and competition: the dual nature of TAM-tumor cell cross-talk in tumor progression.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer and ranks as the sixth most common cancer and the third leading cause of cancer-related death worldwide. Tumor-associated macrophages (TAMs) are predominant immune cells in the tumor microenvironment of HCC, playing critical roles in cancer cell proliferation, epithelial-mesenchymal transition, and metastasis. Reprogramming TAMs from a pro-tumoral phenotype to an anti-tumoral phenotype can enhance macrophage-mediated phagocytosis of HCC cells, improve cytotoxic T cell function, and increase the efficacy of immunotherapies. In this review, we summarize recent findings on how TAMs contribute to HCC development and progression, examine molecular markers and important signaling pathways that regulate TAM function within the tumor microenvironment, and discuss strategies for targeting TAMs at the cellular and molecular levels to treat HCC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.